ASX, MSB, MESOBLAST SUCCESSFULLY COMPLETES PLACEMENT AND ACCELERATED ENTITLEMENT OFFER
Melbourne, Australia; March 14 and New York, USA; March 13, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm…